<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-98653" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Rituximab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hanif</surname>
            <given-names>Nazma</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anwer</surname>
            <given-names>Faiz</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nazma Hanif declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Faiz Anwer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-98653.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This activity centers on rituximab, an anti-CD20 monoclonal antibody pivotal in treating various lymphoproliferative and autoimmune disorders. The program provides an in-depth exploration of rituximab's indications, mechanisms of action, and crucial aspects of its therapeutic application. From lymphomas to autoimmune conditions, the activity elucidates the clinical efficacy of rituximab, shedding light on the intricate mechanisms that underlie its targeting of CD20-positive cells, thereby modulating immune responses and delivering therapeutic effects. Emphasis is placed on essential pharmacological considerations and monitoring parameters vital to ensuring patient safety.</p>
        <p>This activity systematically addresses the validated indications and potential off-label applications of rituximab across diverse medical contexts, equipping healthcare team members with a comprehensive understanding of its adverse effects and contraindications. This knowledge is vital for informed decision-making in treatment planning. The activity aims to enhance healthcare professionals' ability to manage rituximab therapy effectively by outlining monitoring strategies. This optimization of therapeutic outcomes and vigilance&#x000a0;for potential complications contribute to fostering competent and safer patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications and patient profiles suitable for rituximab therapy in the setting of lymphoproliferative and autoimmune disorders.</p></list-item><list-item><p>Screen patients thoroughly for contraindications, previous allergic reactions, and underlying health conditions&#x000a0;prior to initiating rituximab therapy.</p></list-item><list-item><p>Assess the clinical response and monitor for potential adverse reactions during and after rituximab therapy, adjusting treatment plans as necessary.</p></list-item><list-item><p>Develop effective communication&#x000a0;with patients, caregivers, and the healthcare team, discussing the benefits, risks, and expectations related to rituximab treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=98653&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=98653">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-98653.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Rituximab is an anti-CD20 monoclonal antibody that was first approved by the FDA in 1997. Currently,&#x000a0;the drug has received FDA approval for use&#x000a0;in several conditions.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CD20-positive B-cell non-Hodgkin&#x02019;s lymphoma (NHL)
<list list-type="bullet"><list-item><p>Approved for use as a single agent in relapsed/refractory, low-grade, or follicular B cell NHL</p></list-item><list-item><p>Single-agent maintenance therapy for patients with previously untreated follicular B cell NHL who are achieving a complete or some degree of response to combination chemotherapy with rituximab</p></list-item><list-item><p>As a single agent in low-grade non-progressive/stable B cell NHL after Cyclophosphamide, Vincristine, and Prednisolone (CVP) chemotherapy.</p></list-item><list-item><p>In combination with anthracycline-based chemotherapy in previously untreated diffuse large B cell NHL</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia&#x000a0;(SLL): Approved for use in combination with fludarabine and cyclophosphamide to treat newly diagnosed or previously treated CLL.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rheumatoid arthritis (RA): Rituximab&#x000a0;is considered a biologic disease-modifying antirheumatic drug (DMARD) for the treatment of RA.&#x000a0;Rituximab is&#x000a0;approved for use with methotrexate in adult patients who have an inadequate response to anti-TNF therapy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Microscopic olyangiitis (MP) and granulomatosis with polyangiitis (GPA): Approved for use in combination with glucocorticoids.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pemphigus ulgaris (PV): Approved in 2018 for glucocorticoid use for adult patients with moderate to severe disease.<xref ref-type="bibr" rid="article-98653.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>In addition, rituximab has orphan designations for immune thrombocytopenic purpura (ITP) and Rasmussen encephalitis.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>
<bold>Myasthenia gravis</bold>
</p>
        <p>The FDA has recently approved&#x000a0;2 biosimilars of rituximab for adult patients. Biosimilars are drugs that have no clinically significant difference from the reference drug. These have a similar structure, safety profile, and function. Developing biosimilars aims to make medicines more accessible by lowering the cost.<xref ref-type="bibr" rid="article-98653.r2">[2]</xref>&#x000a0;Rituximab-abbs is approved for use in NHL alone or&#x000a0;as part of&#x000a0;a combination chemotherapy regimen and CLL in combination with fludarabine and cyclophosphamide. Rituximab-pvvr has approval for use in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA).</p>
        <p>There are numerous off-label uses of rituximab. According to a retrospective cross-sectional study&#x000a0;performed in the US, the use of rituximab for off-label indications increased from 1.2% in 2009 to 55.6% in 2017.<xref ref-type="bibr" rid="article-98653.r1">[1]</xref>&#x000a0;Off-label uses include refractory autoimmune hemolytic anemia, refractory myasthenia gravis, multiple sclerosis, chronic steroid-refractory GVHD, Hodgkin lymphoma, systemic lupus erythematosus, thrombotic thrombocytopenic purpura, Waldenstrom macroglobulinemia, and membranous nephropathy.</p>
        <p>In combination with hyaluronidase (rituximab-hyaluronidase human), rituximab was approved by the FDA in 2017. This formulation is available for use in the subcutaneous form, giving the advantage of a faster administration over&#x000a0;5 to 7 minutes instead of prolonged infusion times with IV formulations.&#x000a0;This combination is approved for use in chronic lymphocytic leukemia, follicular lymphoma, and diffuse large B-cell lymphoma. One limitation of use is that it can only be given after receiving a full dose of a rituximab product by IV infusion.<xref ref-type="bibr" rid="article-98653.r3">[3]</xref></p>
      </sec>
      <sec id="article-98653.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Rituximab is an anti-CD20 chimeric antibody with human IgG1 immunoglobulin constant regions and variable regions from an anti-CD20 murine antibody. CD20 is a surface transmembrane protein marker expressed on B cells during differentiation from the pre-B cell until the plasma cell stage. CD20 is believed to function as a calcium channel and play a role in the maturation and activation of B cells.<xref ref-type="bibr" rid="article-98653.r4">[4]</xref><xref ref-type="bibr" rid="article-98653.r5">[5]</xref></p>
        <p>Once rituximab is bound to CD20-positive cells, cell death is induced by various mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-mediated-cytotoxicity (CDC), antibody-dependent phagocytosis (ADP), and direct effects of binding of rituximab to CD20.<xref ref-type="bibr" rid="article-98653.r4">[4]</xref>&#x000a0;The mechanism of action of rituximab in autoimmune disease is thought to be due to a disruption in B cells' function in the immune system or a decrease in plasma cell production, as CD20-positive B cells are intermediates in the process of maturation.<xref ref-type="bibr" rid="article-98653.r6">[6]</xref></p>
        <p>The combination of rituximab and hyaluronidase (rituximab-hyaluronidase human) is used in the subcutaneous form. Hyaluronidase causes a reversible increase in permeability of subcutaneous tissue by causing depolymerization of hyaluronan, which leads to an increase in the absorption rate of rituximab.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Rituximab follows a linear pharmacokinetic model.<xref ref-type="bibr" rid="article-98653.r7">[7]</xref>&#x000a0;Intravenously administered rituximab has close to 100% bioavailability.</p>
        <p><bold>Distribution:&#x000a0;</bold>Per the packaging insert available at the FDA, rituximab has a volume of distribution of 3.1 L.</p>
        <p><bold>Metabolism:&#x000a0;</bold>Rituximab is metabolized by various proteases throughout the body and the hepatic CYP450 system of enzymes.</p>
        <p><bold>Elimination:</bold>&#x000a0;The endogenous elimination of&#x000a0;rituximab occurs following its formation of antidrug-monoclonal antibody immune complexes and is mediated by the reticuloendothelial system, most likely via the action of fragment crystallizable-gamma (Fc&#x003b3;)-mediated endocytosis.<xref ref-type="bibr" rid="article-98653.r7">[7]</xref>&#x000a0;The drug's half-life is 18 to 32 days.</p>
      </sec>
      <sec id="article-98653.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms</bold>
</p>
        <p>Rituximab and its biosimilars are approved for use by intravenous infusion. They should not be administered as an IV bolus or push. Patients should be given acetaminophen and antihistamines before each infusion. Rituximab should be diluted in an infusion bag of 0.9% sodium chloride, 5% dextrose in water, or USP. No other drugs should be mixed with it, and patients should be closely monitored for infusion reactions.<xref ref-type="bibr" rid="article-98653.r8">[8]</xref></p>
        <p>Rituximab-hyaluronidase human is approved for subcutaneous use.&#x000a0;The drug should be administered in the subcutaneous abdominal tissue&#x000a0;over 5 to&#x000a0;7 minutes. Patients should be observed for 15 minutes after administration.<xref ref-type="bibr" rid="article-98653.r3">[3]</xref></p>
        <p>
<bold>Adult Dosing&#x000a0;</bold>
</p>
        <p>The following are adult dosing regimens for approved indications. Clinicians should refer to institutional protocols and the packaging insert for indications, premedications, and dosing.</p>
        <p>Relapsed or refractory CD20-positive B-cell NHL:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Monotherapy: 375 mg/m<sup>2</sup>/dose IV weekly for 4 or 8 weeks.</p>
          </list-item>
          <list-item>
            <p>Ibritumomab tiuxetan combination therapy:&#x000a0;250&#x000a0;mg/m<sup>2</sup>/dose IV x 1 on the first day, then on days 7, 8, or 9 of the regimen.</p>
          </list-item>
        </list>
        <p>Previously untreated CD20-positive B-cell NHL:</p>
        <list list-type="bullet">
          <list-item>
            <p>Follicular type - combination chemotherapy:&#x000a0;375 mg/m<sup>2</sup>/dose IV x 1 on day 1 of each cycle for up to 8 cycles.</p>
          </list-item>
          <list-item>
            <p>Follicular type - ibritumomab tiuxetan combination therapy:&#x000a0;250&#x000a0;mg/m<sup>2</sup>/dose IV x 1 on the first day, then on days 7, 8, or 9 of the regimen.</p>
          </list-item>
          <list-item>
            <p>Diffuse large B-cell type - combination chemotherapy:&#x000a0;375 mg/m<sup>2</sup>/dose IV x 1 on day 1 of each cycle for up to 8 cycles.</p>
          </list-item>
        </list>
        <p>Non-progressing&#x000a0;CD20-positive B-cell NHL:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>375 mg/m<sup>2</sup>/dose IV x 1 on days 1, 8, 15, 22, or a 6-month cycle.</p>
          </list-item>
        </list>
        <p>CD-20-positive CLL/SLL:</p>
        <list list-type="bullet">
          <list-item>
            <p>Start 375 mg/m<sup>2</sup>/dose IV x 1 on the day before cycle 1; then 500&#x000a0;mg/m<sup>2</sup>/dose IV x 1 on day 1&#x000a0;of cycle 2 of a 28-day cycle, for 6 cycles.</p>
          </list-item>
        </list>
        <p>Moderate to severe rheumatoid arthritis:</p>
        <list list-type="bullet">
          <list-item>
            <p>1000 mg IV every 2 weeks for 2 doses.</p>
          </list-item>
        </list>
        <p>Granulomatosis with polyangiitis (GPA):</p>
        <list list-type="bullet">
          <list-item>
            <p>Induction:&#x000a0;375 mg/m<sup>2</sup>/dose IV weekly for 4 weeks.</p>
          </list-item>
          <list-item>
            <p>Subsequent:&#x000a0;500&#x000a0;mg/m<sup>2</sup>/dose IV every 2 weeks for 2 doses, then&#x000a0;500&#x000a0;mg/m<sup>2</sup>/dose IV every 6 months.</p>
          </list-item>
        </list>
        <p>Microscopic polyangiitis (MPA)</p>
        <list list-type="bullet">
          <list-item>
            <p>Induction:&#x000a0;375 mg/m<sup>2</sup>/dose IV weekly for 4 weeks; use with glucocorticoids.</p>
          </list-item>
          <list-item>
            <p>Subsequent:&#x000a0;500&#x000a0;mg/m<sup>2</sup>/dose IV every 2 weeks for 2 doses, then&#x000a0;500&#x000a0;mg/m<sup>2</sup>/dose IV every 6 months; start 16 to 24 weeks after the induction dose.</p>
          </list-item>
        </list>
        <p>Moderate to severe pemphigous vulgaris:</p>
        <list list-type="bullet">
          <list-item>
            <p>Start&#x000a0;with 1000 mg IV every 2 weeks for 2 doses, then 500 mg IV every 6 months.</p>
          </list-item>
        </list>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Hepatic dosing for rituximab is undefined.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>Renal impairment requires no dose adjustments.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Rituximab has no known risk of teratogenicity, although there is a risk of transient B-cell depletion based on limited human data.&#x000a0;Females of reproductive potential should obtain a pregnancy test before initiation of treatment and avoid pregnancy by using effective contraception during treatment and for 12 months following the end of treatment.</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Women should avoid breastfeeding during treatment and for 6 months following cessation.</p>
        <p>
<bold>Pediatric patients:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Approved pediatric indications include&#x000a0;CD20-positive B-cell NHL, GPA, and MPA.</p>
          </list-item>
          <list-item>
            <p>Rituximab is used off-label in pediatric patients for relapsed or refractory B-cell precursor ALL, moderate to severe pemphigus vulgaris, refractory autoimmune hemolytic anemia, chronic immune thrombocytopenia (ITP), post-transplant lymphoproliferative disorder (11 months and older), and refractory systemic lupus erythematosus (8 years and older). Consult package inserts or institutional guidelines for dosing and premedication regimens.</p>
          </list-item>
        </list>
        <p><bold>Older&#x000a0;patients:&#x000a0;</bold>Rituximab is a viable treatment in older patients, albeit with diligent monitoring and vigilance.<xref ref-type="bibr" rid="article-98653.r9">[9]</xref></p>
      </sec>
      <sec id="article-98653.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p><bold>Infusion reactions:</bold>&#x000a0;These are the drug's most common and most serious adverse effects. In randomized controlled trials, allergic or anaphylactic reactions were seen in 80% to 90% of patients receiving rituximab.<xref ref-type="bibr" rid="article-98653.r10">[10]</xref>&#x000a0;These are usually seen within 30 to 120 minutes after the first infusion and range from mild to life-threatening. Infusion reactions can include fever, chills, skin rash, urticaria, angioedema, hypotension, ARDS, ventricular fibrillation, shock, anaphylaxis, and death.</p>
        <p><bold>Infections:</bold>&#x000a0;Serious bacterial, viral, and fungal infections can occur. New or reactivated viral infections can include JC virus, herpes simplex, CMV, varicella-zoster, West Nile Virus, and hepatitis B and C. Due to the risk of reactivation, live vaccines are contraindicated during treatment with rituximab. They should be given at least&#x000a0;4 weeks before starting rituximab.</p>
        <p>Reactivation of hepatitis B with fulminant hepatitis, hepatic failure, and death can occur. Before starting rituximab, all patients should be screened with hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc). Patients should also be monitored for hepatitis B reactivation during and after treatment.<xref ref-type="bibr" rid="article-98653.r11">[11]</xref><xref ref-type="bibr" rid="article-98653.r12">[12]</xref></p>
        <p>Reactivation of Hepatitis B and the development of PML (progressive multifocal leukoencephalopathy) due to the JC virus are indications to discontinue rituximab.</p>
        <p>PCP is an opportunistic fungal infection whose prophylaxis is recommended in patients receiving a fludarabine/cyclophosphamide/rituximab combination&#x000a0;to treat CLL.&#x000a0;This combination should be started during treatment and continued for a year following completion, and it is also recommended in patients with GPA and MPA during treatment and for at least&#x000a0;6 months after stopping rituximab.<xref ref-type="bibr" rid="article-98653.r13">[13]</xref></p>
        <p><bold>Hematologic adverse effects:&#x000a0;</bold>Lymphopenia is the most commonly seen hematologic adverse effect. Others include leukopenia, neutropenia, thrombocytopenia, and anemia.</p>
        <p>
<bold>Dermatologic/mucocutaneous reactions:</bold>
</p>
        <p>These include pruritis, alopecia, skin rash, and life-threatening reactions like toxic epidermal necrolysis, paraneoplastic pemphigus, and Stevens-Johnson syndrome.</p>
        <p><bold>Renal adverse effects:&#x000a0;</bold>Tumor lysis syndrome can present with hypocalcemia, hyperphosphatemia, hyperkalemia, hyperuricemia, and acute renal failure within 24 hours of the first infusion. Aggressive hydration and uric acid-lowering therapy should be given to high-risk patients.&#x000a0;Renal toxicity has been seen in trials where rituximab was administered with cisplatin.</p>
        <p><bold>Respiratory adverse effects:</bold>&#x000a0;These include cough, upper respiratory tract infections, rhinitis, epistaxis, bronchospasm, dyspnea, pulmonary toxicity, and ILD.&#x000a0;There have been reports of rare cases of hypersensitivity pneumonitis, status asthmaticus, diffuse alveolar hemorrhage, and bronchiolitis obliterans.<xref ref-type="bibr" rid="article-98653.r10">[10]</xref></p>
        <p><bold>Cardiovascular adverse effects:</bold>&#x000a0;Tachycardia, supraventricular arrhythmias, non-ischemic cardiomyopathy, peripheral edema, chest pain, hypertension.<xref ref-type="bibr" rid="article-98653.r14">[14]</xref></p>
        <p><bold>Gastrointestinal adverse effects:&#x000a0;</bold>Diarrhea, nausea, and vomiting can be seen. Symptoms of abdominal pain should be thoroughly investigated, as there have been reports of bowel obstruction and perforation.</p>
        <p><bold>Neuropsychiatric adverse effects:</bold>&#x000a0;Dizziness, headache, anxiety, depression, and insomnia can occur.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>A limited amount crosses the placental barrier during the first trimester, but crossing increases in the second and third trimesters.&#x000a0;Administration of rituximab during the third trimester can lead to immunosuppression in the neonate.&#x000a0;Levels of rituximab in fetal circulation are similar to maternal levels near term, and live vaccines are contraindicated in the neonate during the first&#x000a0;6 months of birth.<xref ref-type="bibr" rid="article-98653.r15">[15]</xref>&#x000a0;Due to a poor understanding of long-term effects, it is recommended to use effective contraception during treatment with rituximab and for a year after the last dose.<xref ref-type="bibr" rid="article-98653.r16">[16]</xref><xref ref-type="bibr" rid="article-98653.r17">[17]</xref></p>
        <p><bold>Constitutional adverse effects:&#x000a0;</bold>These include asthenia, fever, chills, myalgia, arthralgia, muscle spasms, back pain, night sweats, and fatigue.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>The primary drugs contraindicated for concurrent use with rituximab are live vaccines. Cidofovir and talimogene laherparepvec are also absolutely contraindicated for concurrent use.</p>
      </sec>
      <sec id="article-98653.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Absolute and relative contraindications of the drug exist<xref ref-type="bibr" rid="article-98653.r6">[6]</xref><xref ref-type="bibr" rid="article-98653.r12">[12]</xref>&#x000a0;and include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe, active infection</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to any of the components of the formulation</p>
          </list-item>
          <list-item>
            <p>Severe heart failure</p>
          </list-item>
          <list-item>
            <p>Uncontrolled cardiac disease</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to murine protein</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-98653.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Rituximab has an excellent safety profile, and overdosage has not been experienced in clinical trials. Patients should be regularly monitored for the development of adverse effects.</p>
        <p>Before initiating treatment with rituximab, a CBC, routine chemistries, serum immunoglobulin levels, a chest x-ray, and serologic testing for hepatitis B, C, and HIV should be obtained. If HBsAg or anti-HBc is positive, HBV DNA PCR should be obtained. If HBV DNA is positive, entecavir should be given for prophylaxis. Lamivudine prophylaxis is indicated if HBV DNA is negative.<xref ref-type="bibr" rid="article-98653.r11">[11]</xref></p>
        <p>The following should be regularly monitored during treatment:</p>
        <list list-type="bullet">
          <list-item>
            <p>Development of infusion reactions. Acetaminophen and an antihistamine should be administered before starting the infusion to reduce the incidence of infusion reactions</p>
          </list-item>
          <list-item>
            <p>CBC to look for the development of any cytopenias</p>
          </list-item>
          <list-item>
            <p>Electrolytes and renal function in patients at high risk of tumor lysis syndrome</p>
          </list-item>
          <list-item>
            <p>Cardiac monitoring for patients with a history of cardiac disease</p>
          </list-item>
          <list-item>
            <p>Serum immunoglobulin levels</p>
          </list-item>
          <list-item>
            <p>Liver function tests and HBV DNA in patients with risk of reactivation of hepatitis B</p>
          </list-item>
          <list-item>
            <p>Patients should be monitored for signs and symptoms of opportunistic infections. The neurological function should be assessed to look for the onset of any new deficits.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-98653.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity data for rituximab is not available.&#x000a0;Patients who have had an overdose&#x000a0;are at an increased risk of severe adverse effects,&#x000a0;including fatal infusion-related/severe mucocutaneous reactions.&#x000a0;Symptomatic and supportive measures are recommended.&#x000a0;</p>
      </sec>
      <sec id="article-98653.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Rituximab is a relatively safe and well-tolerated drug, and its off-label use has increased over the years. Patients should be educated&#x000a0;regarding the benefits and risks of rituximab therapy.</p>
        <p>Rituximab therapy requires the efforts and collaboration of a coordinated interprofessional healthcare team. Hypersensitivity reactions (HSR) are commonly seen with rituximab infusions. These can be reduced through premedication and titrated infusions. Priming the IV line with rituximab can have a positive impact. Reducing the HSR rate can reduce the cost for cancer centers, improve patient safety and satisfaction, and prevent delays in treatment. Nurses have a crucial role as members of the multidisciplinary team involved in the care of these patients. Care should be coordinated between the oncologist, other physicians/advanced practice practitioners, nurses, and pharmacists.<xref ref-type="bibr" rid="article-98653.r18">[18]</xref></p>
        <p>Recent evidence has shown a comparable clinical efficacy of subcutaneous and IV rituximab. SC rituximab allows faster delivery of the drug and reduces dosage errors and drug wastage. Faster delivery time allows more patients to be scheduled. Cancer centers should consider the subcutaneous route for most patients with chronic lymphocytic leukemia, follicular lymphoma, and diffuse large B cell lymphoma. The subcutaneous route could also be an alternative for patients with poor IV access.<xref ref-type="bibr" rid="article-98653.r19">[19]</xref><xref ref-type="bibr" rid="article-98653.r20">[20]</xref></p>
      </sec>
      <sec id="article-98653.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=98653&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=98653">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/98653/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=98653">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-98653.s11">
        <title>References</title>
        <ref id="article-98653.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delate</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>KN</given-names>
              </name>
            </person-group>
            <article-title>Indications for Rituximab Use in an Integrated Health Care Delivery System.</article-title>
            <source>J Manag Care Spec Pharm</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>832</fpage>
            <page-range>832-838</page-range>
            <pub-id pub-id-type="pmid">32584674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenwald</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tesser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sewell</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Biosimilars Have Arrived: Rituximab.</article-title>
            <source>Arthritis</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>3762864</fpage>
            <pub-id pub-id-type="pmid">29765782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yelvington</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma.</article-title>
            <source>J Adv Pract Oncol</source>
            <year>2018</year>
            <season>Jul-Aug</season>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>530</fpage>
            <page-range>530-534</page-range>
            <pub-id pub-id-type="pmid">31086689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maloney</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Rituximab: mechanism of action and resistance.</article-title>
            <source>Semin Oncol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>1 Suppl 2</issue>
            <fpage>2</fpage>
            <page-range>2-9</page-range>
            <pub-id pub-id-type="pmid">11842383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pierpont</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Limper</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.</article-title>
            <source>Front Oncol</source>
            <year>2018</year>
            <volume>8</volume>
            <fpage>163</fpage>
            <pub-id pub-id-type="pmid">29915719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Randall</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Rituximab in autoimmune diseases.</article-title>
            <source>Aust Prescr</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>131</fpage>
            <page-range>131-134</page-range>
            <pub-id pub-id-type="pmid">27756976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ryman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Meibohm</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of Monoclonal Antibodies.</article-title>
            <source>CPT Pharmacometrics Syst Pharmacol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>9</issue>
            <fpage>576</fpage>
            <page-range>576-588</page-range>
            <pub-id pub-id-type="pmid">28653357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kosmidis</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Practical considerations on the use of rituximab in autoimmune neurological disorders.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-105</page-range>
            <pub-id pub-id-type="pmid">21179602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mielnik</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lie</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bakland</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Loli</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Kristianslund</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>R&#x000f8;devand</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lexberg</surname>
                <given-names>&#x000c5;S</given-names>
              </name>
              <name>
                <surname>Kvien</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register.</article-title>
            <source>Drugs Aging</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>8</issue>
            <fpage>617</fpage>
            <page-range>617-626</page-range>
            <pub-id pub-id-type="pmid">32648248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kasi</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Tawbi</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Oddis</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective.</article-title>
            <source>Crit Care</source>
            <year>2012</year>
            <month>Aug</month>
            <day>31</day>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>231</fpage>
            <pub-id pub-id-type="pmid">22967460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nixon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ogden</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Woywodt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dhaygude</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Infectious complications of rituximab therapy in renal disease.</article-title>
            <source>Clin Kidney J</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>455</fpage>
            <page-range>455-460</page-range>
            <pub-id pub-id-type="pmid">28852481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buch</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Smolen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Betteridge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Breedveld</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Burmester</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D&#x000f6;rner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ferraccioli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gottenberg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kvien</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Mariette</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Martin-Mola</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pavelka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tak</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>van der Heijde</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>van Vollenhoven</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>P</given-names>
              </name>
              <collab>Rituximab Consensus Expert Committee</collab>
            </person-group>
            <article-title>Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>909</fpage>
            <page-range>909-20</page-range>
            <pub-id pub-id-type="pmid">21378402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maertens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cesaro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maschmeyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Einsele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Alanio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Lagrou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Melchers</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Helweg-Larsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matos</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bretagne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cordonnier</surname>
                <given-names>C</given-names>
              </name>
              <collab>5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN)</collab>
            </person-group>
            <article-title>ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>71</volume>
            <issue>9</issue>
            <fpage>2397</fpage>
            <page-range>2397-404</page-range>
            <pub-id pub-id-type="pmid">27550992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheungpasitporn</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kopecky</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bharucha</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy.</article-title>
            <source>J Renal Inj Prev</source>
            <year>2017</year>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-25</page-range>
            <pub-id pub-id-type="pmid">28487867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakravarty</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Kelman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy outcomes after maternal exposure to rituximab.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Feb</month>
            <day>03</day>
            <volume>117</volume>
            <issue>5</issue>
            <fpage>1499</fpage>
            <page-range>1499-506</page-range>
            <pub-id pub-id-type="pmid">21098742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Traila</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dima</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Achimas-Cadariu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Micu</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era.</article-title>
            <source>Cancer Manag Res</source>
            <year>2018</year>
            <volume>10</volume>
            <fpage>1517</fpage>
            <page-range>1517-1526</page-range>
            <pub-id pub-id-type="pmid">29942153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leroy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rigot</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Leroy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Decanter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Le Mapihan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Parent</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Le Guillou</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Yakoub-Agha</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dharancy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Noel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vantyghem</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Immunosuppressive drugs and fertility.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2015</year>
            <month>Oct</month>
            <day>21</day>
            <volume>10</volume>
            <fpage>136</fpage>
            <pub-id pub-id-type="pmid">26490561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laudati</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Knezevic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Barton-Burke</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment.</article-title>
            <source>Clin J Oncol Nurs</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>407</fpage>
            <page-range>407-414</page-range>
            <pub-id pub-id-type="pmid">30035788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aucoin</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Crosbie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lye</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Christofides</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mitha</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Update on the subcutaneous administration of rituximab in Canadian cancer centres.</article-title>
            <source>Curr Oncol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-116</page-range>
            <pub-id pub-id-type="pmid">32489254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-98653.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boehnke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dadabhoy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lugtenburg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rule</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rummel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Badoux</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.</article-title>
            <source>Adv Ther</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>2210</fpage>
            <page-range>2210-2231</page-range>
            <pub-id pub-id-type="pmid">28983819</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
